The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of rifaximin in patients with early-stage HER2 positive breast cancer with gastrointestinal toxicities related to pertuzumab-based therapy.
 
Saranya Chumsri
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Athenex; Athenex; bioTheranostics; bioTheranostics (Inst); Eisai; Immunomedics; Immunomedics; Immunomedics; Novartis; Novartis; Puma Biotechnology; Seagen; Syndax
Research Funding - Array BioPharma; Merck; Salix
 
Elizabeth Harlos
No Relationships to Disclose
 
Heshan Liu
No Relationships to Disclose
 
Emily R. Stark
No Relationships to Disclose
 
Aixa Elena Soyano Muller
Honoraria - FLASCO; OncLive/MJH Life Sciences
Consulting or Advisory Role - Lilly; Novartis
 
Morgan Weidner
No Relationships to Disclose
 
Lauren Cornell
No Relationships to Disclose
 
Beverly J. Roseberry
No Relationships to Disclose
 
Pooja Prem Advani
Stock and Other Ownership Interests - Abbvie (I); Alpha2 Pharmaceuticals (I); NanoString Technologies (I); Sorrento Therapeutics (I)
Honoraria - Ascentage Pharma Group (I); AstraZeneca (I)
Consulting or Advisory Role - Ascentage Pharma (I); AstraZeneca (I); BMS (I); Puma Biotechnology
Research Funding - Agendia; Ascentage Pharma (I); AstraZeneca (Inst); Atossa Therapeutics (Inst); Ayala Pharmaceuticals (Inst); Bristol Myer Squibb (I); Caris Life Sciences (Inst); Genentech/Roche; Gilead Sciences (Inst); Seagan (Inst)
Patents, Royalties, Other Intellectual Property - patent pending on PCT-US2020-067237 (cancer vaccine platform) (I)
Travel, Accommodations, Expenses - Caris Life Sciences; Tempus (I)
 
Brenda Ernst
No Relationships to Disclose
 
Rohit Rao
No Relationships to Disclose
 
Kostandinos Sideras
No Relationships to Disclose
 
Alvaro Moreno-Aspitia
Stock and Other Ownership Interests - Merrimack
Research Funding - Genentech (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Sermonix Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from the development of a xenograft model. Royalties were assigned to go to my institution and not personally
 
Maria I. Vazquez-Roque
Consulting or Advisory Role - Rebiotix
Research Funding - Rebiotix